ODAC Votes To Continue Dostarlimab Research in dMMR/MSI-H Locally Advanced Rectal CancerFebruary 12th 2023
In an 8 to 5 vote, ODAC voted in support of launching 2 single-arm trials seeking to characterize the risk-benefit profile of dostarlimab for patients with dMMR/MSI-H locally advanced rectal cancer.
NCCN Guidelines Support Sodium Thiosulfate to Mitigate Cisplatin-Induced Hearing Loss in Pediatric Patients With CancerFebruary 11th 2023
According to Fennec Pharmaceuticals, the National Comprehensive Cancer Network is updating it guidelines to recommend injections of sodium thiosulfate to reduce the risk of ototoxicity in pediatric patients receiving cisplatin.
Pembrolizumab With or Without Chemotherapy Continues to Show Survival Benefit Over Cetuximab Plus Chemotherapy in Recurrent/Metastatic HNSCCFebruary 7th 2023
Patients with head and neck squamous cell carcinoma continued to displayed a survival benefit with pembrolizumab at a 4-year follow-up.
Oncology Nurses Delve Into The Relationship Between Positive Psychology and Symptom Burden in CRC SurvivorshipFebruary 7th 2023
A study in the Oncology Nursing Forum highlights which factors are associated with positive psychology and symptom burden in colorectal cancer survivors.
Switch Maintenance Regimens Demonstrate Similar Efficacy for Patients with RAS Wild-Type mCRCFebruary 6th 2023
Patients with RAS-wild-type metastatic colorectal cancer did not experience a benefit in terms of response rate or survival when cetuximab was added to the first cycle of chemotherapy.
Nanvuranlat Linked To Better PFS Compared With Placebo in Patients With Pretreated, Advanced BTCFebruary 5th 2023
Nanvuranlat inspired better progression-free survival in patients with advanced, pretreated refractory biliary tract cancer, meeting the primary end point of a phase 2 trial.
Newer Therapies Outperform Sorafenib in Real-World Analysis of Patients With HCCFebruary 4th 2023
Newer agents approved for frontline hepatocellular carcinoma, including lenvatinib, and atezolizumab/bevacizumab, yielded superior survival outcomes than sorafenib in a real-world setting.
Magrolimab Plus Rituximab/Chemo Delivers Responses in Relapsed/Refractory DLBCLFebruary 3rd 2023
At 11.3 months of follow-up, magrolimab, rituximab, gemcitabine, and oxaliplatin yielded an overall response rate of 51.5%, including a complete response rate of 39.4%, among patients with relapsed or refractory diffuse large B-cell lymphoma.
Sacituzumab Govitecan Receives Indication for Unresectable, Locally Advanced or Metastatic HR+/HER2- Breast CancerFebruary 3rd 2023
The FDA has approved sacituzumab govitecan-hziy for patients with unresectable locally advanced or metastatic hormone receptor-positive, HER2-negative breast cancer.
Ibrutinib Plus Prednisone Does Not Improve Response Rates in cGVHDFebruary 2nd 2023
First-line ibrutinib plus prednisone missed the primary endpoint in the phase 3 iNTEGRATE trial by not improving the response rate in patients with chronic graft-versus-host-disease compared with placebo plus prednisone.
Real-World Data Confirm Ide-cel Safety and Efficacy for Patients With Multiple MyelomaFebruary 2nd 2023
Although most patients in the real-world setting would not have met the clinical trial eligibility criteria, the efficacy and safety outcomes with idecabtagene vicleucel were similar for both sets of patients with multiple myeloma.
ASH Data Offer Treatment Direction for Oncology Nursing ProfessionalsFebruary 1st 2023
Nilesh Kalariya, PhD, AGPCNP-BC, AOCNP; and Laura J. Zitella, MS, RN, ACNP-BC, AOCN, discuss practice-changing presentations from the 64th American Society of Hematology Annual Meeting and Exposition.
FDA Approves Oral SERD Elacestrant for ESR1-Mutant ER+, HER2– Metastatic Breast CancerJanuary 27th 2023
The FDA has granted an accelerated approval to elacestrant (Orserdu) for the treatment of patients with estrogen receptor–positive, HER2-negative advanced or metastatic breast cancer following at least 1 prior lines of endocrine therapy.
FDA Grants Pirtobrutinib Accelerated Approval for Relapsed/Refractory MCLJanuary 27th 2023
Pirtobrutinib has been approved for patients with mantle cell lymphoma. The prescribing label comes with warnings for infections, hemorrhage, cytopenias, atrial fibrillation and flutter, second primary malignancies, and embryo-fetal toxicity.
Neoadjuvant Treatment Crosses Cost-Effective Threshold Vs Upfront Surgery in Pancreatic CancerJanuary 27th 2023
Neoadjuvant chemoradiation followed by pancreaticoduodenectomy resulted in 0.14 more quality-of-life years than upfront surgery followed by adjuvant chemotherapy in patients with resectable pancreatic cancer.